Precision Biosciences INC Form 4 insider transactions

Melinda Brown, a Director at Precision Biosciences Inc., has increased her beneficial ownership in the company through an open market purchase of common stock.

Kevin Buehler, a Director at Precision Biosciences Inc. (DTIL), has acquired 5,076 shares of common stock, increasing his beneficial ownership to 28,137 shares.

Precision Biosciences, Inc. Chief Financial Officer John Alexander Kelly was granted 82,750 restricted stock units on June 2, 2025, as reported in a recent SEC Form 4 filing.

Precision Biosciences Director Geno J. Germano reported the vesting of 9,826 Restricted Stock Units into common stock and the grant of 21,000 new Restricted Stock Units.

Precision Biosciences, Inc. Director Shari Lisa Pire reported the vesting of 9,826 Restricted Stock Units into common stock and the grant of an additional 21,000 Restricted Stock Units.

Stanley Frankel, a Director at Precision Biosciences Inc. (DTIL), reported an increase in his beneficial ownership of common stock and a new grant of Restricted Stock Units (RSUs) through recent transactions.

Precision Biosciences Director Kevin Buehler has reported the vesting of 9,826 Restricted Stock Units (RSUs) and the acquisition of 21,000 new RSUs, aligning his interests with the company's long-term performance.

Precision Biosciences Director Melinda Brown has reported changes in her beneficial ownership, including the vesting of 9,826 Restricted Stock Units into common stock and the grant of an additional 21,000 Restricted Stock Units.

Precision Biosciences, Inc. has granted 50,000 restricted stock units to its Chief Research Officer, J. Jefferson Smith, as part of his compensation, vesting over three years.

Precision BioSciences, Inc. has granted 50,000 restricted stock units to Dario Scimeca, the company's General Counsel and Secretary, as part of his compensation.

Precision Biosciences' President and CEO, Michael Amoroso, was granted 203,390 restricted stock units, aligning his incentives with long-term company performance.

Director Kevin Buehler of Precision BioSciences, Inc. (DTIL) purchased 4,523 shares of common stock at an average price of $4.67 on March 26, 2025.

Director Melinda Brown purchased 1,839 shares of Precision BioSciences (DTIL) at $4.75 per share on March 26, 2025, increasing her direct holdings.

Director Geno Germano purchased 3,250 shares of Precision BioSciences (DTIL) at $5.30 per share, increasing his total holdings.

CEO Michael Amoroso reports vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Chief Research Officer Smith J. Jefferson of Precision BioSciences reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

John Alexander Kelly, CFO of Precision BioSciences, reports the vesting of Restricted Stock Units (RSUs) on March 3, 2025, according to a Form 4 filing with the SEC.

Dario Scimeca, General Counsel and Secretary of Precision BioSciences, sold shares to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).

Precision BioSciences' General Counsel, Dario Scimeca, sold 8,928 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Precision BioSciences' Chief Financial Officer, John Alexander Kelly, exercised stock options and received restricted stock units on January 20, 2025, resulting in changes to his beneficial ownership.

Precision BioSciences CEO Michael Amoroso acquired shares through RSU vesting and sold a portion to cover tax obligations, as detailed in a recent SEC Form 4 filing.

J. Jefferson Smith, Chief Research Officer at Precision BioSciences, sold shares to cover tax obligations following the vesting of restricted stock units.

Director Geno Germano of Precision BioSciences, Inc. (DTIL) reports purchasing 3,605 shares of common stock at an average price of $4.49 on December 30, 2024.

Precision BioSciences director Kevin Buehler purchased 4,320 shares of common stock at a weighted average price of $4.88 on December 27, 2024.

Precision BioSciences' Chief Financial Officer, John Alexander Kelly, purchased 2,113 shares of common stock at $4.75 per share on December 27, 2024.

Director Melinda Brown of Precision BioSciences acquired 3,016 shares of common stock at an average price of $4.55 on December 26, 2024.

Precision BioSciences' Chief Financial Officer, John Alexander Kelly, purchased 3,000 shares of the company's common stock at a price of $6.76 per share.

John Alexander Kelly, CFO of Precision BioSciences, reports the vesting of restricted stock units.

Dario Scimeca, General Counsel and Secretary of Precision BioSciences, reports the vesting of Restricted Stock Units and subsequent sale of shares to cover tax obligations.

Michael Amoroso, CEO of Precision BioSciences, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.